G35
Conditions
Interventions
Group 1: All patients treated with tryptophan immunoadsorption for MS relapse as part of their standard medical care are analysed.
Sponsors
Klinik für NeurologieKlinikum Lüdenscheid
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: acute MS relapse with indication for escalation therapy with immunoadsorption
Exclusion criteria
Exclusion criteria: Patient doesn´t agree to participate. Treating physician doesn´t want to participate in the investigation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main outcome parameter for efficacy of immunoadsorption is change of acute ms relapse related disability. Clinical evaluation is performed before the first IA and after the last IA of the treatment series. Functional MS-related disability will be assessed with the EDSS (expanded disability status scale). In patients with optic neuritis also the best corrected visual acuity will be used. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability and safety of immunoadsorption. IA treatments will be documented in CRF´s. Parameter for safety and tolerability are: blood pressure, vascular access, fibrinogen concentration, treated plasma volume, general condition of the patient. | — |
Countries
Germany
Contacts
Public ContactReinhard Klingel
Apherese Forschungsinstitut
Outcome results
None listed